Colorectal Adenocarcinoma

Oncology·MeSH: Colonic Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

15 drugs in development·5 companies·12 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
calcium gluconate in	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(5)

Drug	Company
FOLFIRI+cetuximab	IGM Biosciences, Inc. (IGMS)
FOLFOX-4	IGM Biosciences, Inc. (IGMS)
FOLFOX-7	IGM Biosciences, Inc. (IGMS)
Leucovorin	Amneal Pharmaceuticals, Inc. (AMRX)
Leucovorin Calcium	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 2(2)

Drug	Company
Cabozantinib	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFOX regimen	IGM Biosciences, Inc. (IGMS)

Phase 1(6)

Drug	Company
BET Bromodomain Inhibitor ZEN-3694	FATE THERAPEUTICS INC (FATE)
Cemiplimab	Crinetics Pharmaceuticals, Inc. (CRNX)
Emavusertib	Amneal Pharmaceuticals, Inc. (AMRX)
Encorafenib	FATE THERAPEUTICS INC (FATE)
FOLFIRI	IGM Biosciences, Inc. (IGMS)
Pidnarulex	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 4(1)

Drug	Company
Cetuximab	IGM Biosciences, Inc. (IGMS)

BioSniper tracks 15 drugs in development for Colorectal Adenocarcinoma across 5 companies.

There are 12 clinical trials targeting Colorectal Adenocarcinoma tracked by BioSniper.

The estimated prevalence of Colorectal Adenocarcinoma is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.